Biotech CEO Compensation: The Real Inflection Point

The real inflection point in biotech CEO compensation isn’t between early and late clinical trials. It’s the leap from pre-clinical to clinical. In this data drop, pulled directly from the Thelander Platform, we looked at how median total cash, founder and non-founder equity changes across biotech stages of development.

Pre-Clinical → Clinical
Median total cash: $329,067 → $447,500
Median total founder equity: 16.00% → 9.00%
Median non-founder equity: Steady at 5.00%

Clinical Phase I → Phase II/III
Median total cash: $452,500 → $445,720
Median total founder equity: 7.99% → 9.90%
Median non-founder equity: 5.00% → 4.74%

The takeaway? CEO total cash jumps significantly between the pre-clinical and clinical phases of biotech development, with a corresponding decrease in founder equity while non-founder equity stays steady. There is much less of a difference in CEO comp between the earlier and later clinical phases, suggesting the main difference is between pre-clinical and clinical.

The biotech stage of development filter is available on the Thelander Platform. To trial the platform for no charge and access customized real-time compensation data, fill out the survey today.

Categorised in: Data Drops

This post was written by jthelander